ADA: AstraZeneca's Farxiga scores in kidney outcomes study

AstraZeneca doesn't yet have the same heart-helping outcomes data for Farxiga that its rivals can boast for their SGLT2 contenders. But the company thinks it may have something better.

Sunday, the annual Scientific Sessions of the American Diabetes Association in San Francisco, the British drugmaker trotted out results from an outcomes study, dubbed Declare, that showed Farxiga could trigger a 47% reduction in the combined risk of kidney function decline, end-stage renal disease and renal death in Type 2 diabetes patients.